Prognostic significance of p53 and Bcl-2 in acute lymphoblastic leukemia

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1391-1398

  Sahu, Geeta Ram ^a   Das, Bibhu Ranjan ^a  

^a not available ^*

Author keywords

Acute lymphoblastic leukemia; Bcl 2; p53; Prognosis

Indexed keywords

LEUKOCYTE ANTIGEN; PRIMER DNA; PROTEIN BCL 2; PROTEIN P53;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHEMISTRY; ENZYME IMMUNOASSAY; EXON; GENE EXPRESSION REGULATION; GENETICS; HALF LIFE TIME; HUMAN; IMMUNOPHENOTYPING; METABOLISM; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTIGENS, CD; BLOTTING, WESTERN; DNA PRIMERS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HALF-LIFE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036833979     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1391     Document Type: Article

References (56)

1. Lane DP: p53 Guardian of the genome. Nature 15: 358, 1992.
2. Lane DP and Benchimol S: p53: oncogene or antioncogene? Genes Dev4: 1-8, 1990.
3. Vogelstein B and Kinzlr KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
4. Wattel E, Preudhomma C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P and Fenoux P: p53 mutations are associated with resistance to chemotherapy and short survival in haematologic malignancies. Blood 84: 3148-3157, 1994.
5. Hsiao MH, Yu AL, Yeargin J, Ku D and Haas M: Non-hereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 83: 2922-2930, 1994. (Pubitemid 24142725)
6. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shaw LE and Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84: 3105-3112, 1994. (Pubitemid 24328104)
7. Zhu YM, Foroni L, McQuaker IG, Papionnou M, Haynes A and Russel N: Mechanisms of relapse in acute leukemia. Involvement of p53 mutated subclones in disease progression acute lymphoblastic leukemia. Br J Cancer 79: 1151-1157, 1999. (Pubitemid 29087889)
8. Frånser A and Evan GM: A license to kill. Cell 85: 781-784, 1996.
9. Reed JC: Bcl-2 family proteins: relgulators of chemoresistance in cancer. Toxicol Lett 82: 155-158, 1995.
10. Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haematopoietic cells survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
11. Van Rooij H, Miyashita T and Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993. (Pubitemid 23013689)
12. Compana D, Coustan-Smith E, Manabe A, Buschte M, Raimondi SC, Behm FG, Ashmun R, Arico M, Biondi A and Pui CH: Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of Bcl-2 protein. Blood 81: 1025-1031, 1993. (Pubitemid 23054841)
13. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ and Hall AG: The relationship between Bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 88: 105-109, 1994. (Pubitemid 24293860)
14. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M and Martiat P: High expression of Bcl-2 is the tule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation and is not correlated with the prognosis. Ann Hematol 69: 17-24, 1994. (Pubitemid 24255444)
15. Coustan-Smith D, Kitanaka A, Pui CH, McNinch L, Elans WE, Raimondi SC, Behm FG, Arico M and Campana D: Clinical relevance of Bcl-2 overexpression in child acute lymphoblastic leukemia. Blood 87: 1140-1146, 1996. (Pubitemid 26043542)
16. Uckun FM, Reaman G, Steinherz PG, Arthur DC, Sather H, Trigg M, Tubergen D and Gaynon P: Improve clinical outcome for children with T-lineagc acute lymphoblastic leukemia after contemporary chemotherapy: a children's Cancer Group Study. Leuk Lymphoma 24: 57-70, 1996.
17. Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P and Reaman G: CD2 antigen expression on leukemia cells as a prediztor of event free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a children's Cancer Group study. Blood 88: 4288-4295, 1996. (Pubitemid 26399176)
18. Uckun FM and Song CW: Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 81: 1323-1332, 1993. (Pubitemid 23067371)
19. Uckun FM, Gaji-Peczalska KJ, Provisor AJ and Heerema NA: Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 73: 271-280, 1989. (Pubitemid 19040987)
20. Uckun FM and Ledbetter JA: Immunobiologic differences between normal and leukemic human B-cell precursors: Proc Natl Acad Sei USA 85: 8603-8607, 1988. (Pubitemid 19025005)
21. Uckun FM, Myers DE, Jaszcz W, Haissig S, Gajl-Peczalska K and Ledbetter JA: Temporal association of CD40 antigen expression with discrete stage of human B-cell ongogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkins's lymphoma cells. Blood 76: 2449-2456, 1990.
22. Uckun CW, Jaszcs W, Ambros JL, Fauci AS, Gaji-Peczalska KJ, Song CW, Wick MR, Myers DE, Waddick KG and Ledbetter JA: Detailed studies on expression and function of CD19 surface determinant using B43 monoclonal antibody. Blood 71: 13-29, 1988.
23. Uckun FM, Jaszcz W, Chandan-Langlie M, Waddick KG, Gaji-Peczalska K and Song CW: Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J Clin Invest 91: 1044-1051, 1993. (Pubitemid 23095280)
24. Hayashi K: PCR methods and applications. Oxford University Press 1:34-38, 1991.
25. Kaplan EI and Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
26. Cox DR: Regression models and life-tables. J Royal Stat Soc B 34: 187-220, 1972.
27. Hermine O, Haioun C, Lepage E, doAgay MF, Briere J, Lavignac C, Fillet G, Salles G, Mardleau JP, Diebold J, Reyas F and Gaulard P: Prognostic significance of Bcl-2 expression in aggressive non-Hodgkin's lymphoma Groupe d'Etude des Lymphomes del'Adulte (GELA). Blood 87: 265272, 1996.
28. Kondo E, Yosino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J and Akagi T: Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 145: 330-337, 1994. (Pubitemid 24245833)
29. Miller D, Coccia P, Bleyer W, Lukens JN, Siegel SE, Sather H and Hammond GD: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the children's Cancer study Group. J Clin Oncol 7: 1807-1815, 1989. (Pubitemid 20014327)
30. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L and Janossy G: Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leuk Lymphoma 9: 1191-1198, 1995.
31. Russel NH, Hunter AE, Bradbury D, Zhu YM and Keith F: Biological features of leukemic cells associateds with autonomous growth and reduced survival in acute myeloblastic leukemia. Leuk Lymphoma 16: 223-229, 1995.
32. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 88: 386-401, 1996. (Pubitemid 26240369)
33. Campos L, Rauault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP and Guyotat D: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096, 1993. (Pubitemid 23162130)
34. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G and Bhalla K: High levels of p26 Bcl-2 oncoprotein taxol-induced apoptosis of human pre-B leukemia cells. Leukemia 8: 1960-1969, 1994.
35. Uekun FM, Yang Z, Sather H, Steinherz P, Nachman J, Boström B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G and Gaynon P: Cellular expression of antiapeptotic Bcl-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a children's Cancer Group Study. Blood 89: 3769-3777, 1997. (Pubitemid 27227101)
36. Prokocimer M and Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells. Projection on the haematologic cell lineages. Blood 84: 2391-2411, 1994. (Pubitemid 24317369)
37. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA and Porta GD: Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79: 1291-1298, 1992.
38. Findley HW, Lubing GU, Yeager AM and Zhou M: Expression and regulation of Bc!-2, Bcl-Xl and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89: 2986-2993, 1997. (Pubitemid 27172586)
39. Lin FR, Yao EG, Zuo LF, Xu SR, Ren JH and Liusy Wei JP: Correlative study on the expression of p53 and DNA ploidy in acute non-lymphoblastic leukemia. J Tonsji Med Univ 15: 143-146, 1995.
40. Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A and Fenaux P: Detection of p53 mutations in haematological malignancies. Comparision between immuno-cytochemistry and DNA analysis. Leukemia 8: 1342-1349, 1994. (Pubitemid 24262491)
41. Campos L, Sabido O, Sebba C, Charrin C, Bertheas MF, Fiére D and Guyotat D: Expression of Bcl-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 10: 434-438, 1996. (Pubitemid 26128781)
42. Salomons GS, Brady HJM, Verwijs-Janssen M, van den Berg JD, Hart AAM, van den Berg H, Behrendt H, Hählen K and Smets LA: The mic cells and is highly variable in childhood acute leukemia. Int J Cancer 71: 959-965, 1997.
43. Lauria F, Raspador D, Rondelli D, Venturia MA, Facchini M, Visani G, Farconi F and Tura S: High Bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 11: 2075-2078, 1997. (Pubitemid 28043692)
44. Karakas T, Maurer U, Weidmann E, Miething, CC, Hoelzer D and Bergmann L: High expression of Bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 9: 159-165, 1998. (Pubitemid 28123617)
45. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernaardi S, Tamassia MG and Sacchi S: Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 80: 98-102, 1995.
46. Banker DE, Groudine M, Norwood T and Appelbaum FR: Measurement of spontaneous and therapeutic agent-induced apoptosis with Bcl-2 protein expression in acute myeloid leukemia. Blood 89: 243-255, 1997. (Pubitemid 26428199)
47. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F and Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lungcancer. Br J Cancer 71: 1003-1007, 1995.
48. Alderson LM, Castleberg RL, Harsh GR, Louis DN and Henson JW: Human gliomas with wild-type p53 express Bcl-2. Cancer Res 55: 999-1001, 1995.
49. Elledge RM and Allred DC: The p53 tumour suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39-47, 1994. (Pubitemid 24322246)
50. Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM and Findley HW: Incidence and prognostic significance of mdm-2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14: 61-67, 2000. (Pubitemid 30068374)
51. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I and Haines DS: Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 15:1158-1162,1997. (Pubitemid 27106303)
52. Matsushima AY, Cesarman E, Chadburn A and Knowles DM: Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144: 573-584, 1994. (Pubitemid 24176763)
53. Ueda H, Ullrich SJ, Gangemi JD, Kappel CC, Ngo L, Feitelson MA and Jay G: Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9: 41-47, 1995.
54. Pignon JM, Vinatier I, Fanen P, Jonveaux P, Tournilhac O, Imbert M, Rochant H and Goossens M: Exhaustive analysis of the p53 gene coding sequence by denaturing gradiant gel electrophoresis: application to the detection of point mutations in acute leukemias. Hum Mutat 3: 126-132, 1994.
55. Vogelstein B: A deadly inheritance. Nature 348: 681-682, 1990.
56. Moll UM, Riou G and Levine AJ: Two distinct mechanism alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sei USA 89: 7262-7266, 1992. Industrial Research